文献速递造血干细胞移植与细胞治疗

BMT CTN 1702:替代供者移植结局与MUD的前瞻性比较

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.
PubMed 文献 · Blood Adv · 2026-01-01

BMT CTN 1702为多中心前瞻性生物学分配试验,用供者搜索预后评分将1179例患者分配至8/8 HLA相合无关供者(MUD)、单倍体(HAPLO)、不全相合无关供者(MMUD)或脐血(UCB)移植。多因素分析显示HAPLO和MMUD总生存与MUD无统计学差异,UCB生存较差;接受PTCy者HAPLO和MMUD的3-4级急性GVHD和慢性GVHD风险高于MUD。

要点

  • HAPLO和MMUD移植总生存与MUD无统计学差异,可加速移植。
  • UCB移植生存 inferior,治疗相关死亡率和无病生存均较差。
  • 接受PTCy者HAPLO和MMUD的3-4级急性GVHD风险高于MUD。

核心结论

  • 与MUD相比,HAPLO和MMUD移植生存无统计学差异,UCB生存较差。
  • 接受PTCy者HAPLO和MMUD的3-4级急性GVHD和慢性GVHD风险高于MUD。
  • 当找到MUD可能性低时,可用HAPLO或MMUD加速移植。

研究设计与样本

  • 多中心前瞻性生物学分配试验BMT CTN 1702,注册号NCT03904134。
  • 共1179例患者(93%为成人),用供者搜索预后评分分配至MUD、HAPLO、MMUD或UCB。
  • 移植例数:MUD 772例、HAPLO 254例、MMUD 112例、UCB 41例。
  • 从入组到移植中位时间:MUD 3.7个月、HAPLO 3.4个月、MMUD 3.9个月、UCB 3.8个月。
  • PTCy使用率:MUD 23.9%、HAPLO 83.9%、MMUD 65.2%、UCB 0%。

主要发现

  • 多因素分析中,与MUD相比UCB总生存较低(HR 2.65;P<.001),HAPLO和MMUD无统计学差异(HR分别为1.08和1.18)。
  • 复发风险在各供者类型间无显著差异。
  • 与MUD相比,UCB治疗相关死亡率较高(HR 3.31;P<.001)、无病生存较差(HR 1.99;P=.002),HAPLO和MMUD无差异。
  • 接受PTCy者,与MUD相比HAPLO和MMUD的3-4级急性GVHD风险增加(HR 2.39,P=.017;HR 2.53,P=.038)。
  • 接受PTCy者,与MUD相比HAPLO和MMUD的慢性GVHD风险增加(HR均为1.71;P=.028和.080)。

临床怎么用

  • 当找到MUD可能性低时,可选用HAPLO或MMUD以加速移植。
  • 使用PTCy的HAPLO或MMUD移植需关注3-4级急性GVHD和慢性GVHD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Newer approaches to control alloreactivity may produce similar transplant outcomes using HLA-mismatched donors vs HLA-matched unrelated donors (MUD). However, prospective comparisons are lacking. BMT CTN 1702 used a donor search prognosis score to assign patients to an 8/8 HLA MUD or the center's preference of haploidentical related donors (HAPLO), mismatched unrelated donors (MMUD), or umbilical cord blood (UCB). Outcomes of MUD were compared to HAPLO, MMUD, and UCB transplantation after adjusting for covariates. Patients (n = 1179 [93% adults]) underwent transplantation with MUD (n = 772), HAPLO (n = 254), MMUD (n = 112), and UCB (n = 41) at a median of 3.7, 3.4, 3.9, and 3.8 months from enrollment. Posttransplant cyclophosphamide (PTCy) was used in 23.9%, 83.9%, 65.2%, and 0% of MUD, HAPLO, MMUD, and UCB. In multivariate analyses, compared to MUD, survival was lower for UCB (hazard ratio [HR], 2.65; P< .001) but not statistically different for HAPLO and MMUD (HRs, 1.08 and 1.18, respectively). Relapse risk was not significantly different by donor, but treatment-related mortality (HR, 3.31; P< .001) and disease-free survival (HR, 1.99; P = .002) were inferior for UCB but not different for HAPLO and MMUD than MUD. In patients who received PTCy, HAPLO and MMUD were associated with increased grade 3 or 4 acute graft-versus-host disease (GVHD; HR, 2.39 [P = .017] and 2.53 [P = .038], respectively) and chronic GVHD (HR, 1.71 for both; P = .028 and .080) than MUD, but other outcomes were not different. HAPLO or MMUD may be used to expedite transplantation when finding MUD is unlikely. This study was registered at www.clinicaltrials.gov as NCT03904134.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bashey A, Logan B, Hill L, et al. Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial. Blood Adv. 2026. PMID: 42263667. doi:10.1182/bloodadvances.2026020355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。